Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia
Recruiting · NCT04109820 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Pittsburgh
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
MitoQ is commercially available as a dietary supplement and it has been tested as a potential drug in other diseases, but it has never been tested in patients with sickle cell disease. The goal of this research is to study if MitoQ, a molecule that works as an antioxidant by removing potentially damaging agents in a living organism, improves platelet function in patients with sickle cell disease (SCD).
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Subjects
- African American
- Patients with sickle cell anemia
- 18 years old or older
- Control
- African American healthy controls
- 18 years of age or older
Exclusion criteria
- Pregnancy,
- Known hypertension,
- Hemodialysis and active obstructive sleep apnea requiring treatment.
- Use of anti-platelet medication or have had transfusion in the 4 weeks prior to enrollment.
Where it is running
5 locations listed across 1 US state.
- Magee Women's Hospital - Pittsburgh, Pennsylvania, United States
- UPMC Montefiore - Pittsburgh, Pennsylvania, United States
- UPMC Presbyterian - Pittsburgh, Pennsylvania, United States
- Children's Hospital of Pittsburgh - Pittsburgh, Pennsylvania, United States
- Hillman Cancer Center - Pittsburgh, Pennsylvania, United States